SIRT1-IN-1
Based on 2 publication(s) in Google Scholar
SIRT1-IN-1 is a selective SIRT1 inhibitor with an IC50 of 0.205 μM. SIRT1-IN-1 inhibits SIRT2 with an IC50 of 11.5 μM. SIRT1-IN-1, a indole, is a cytomegalovirus (CMV) inhibitors and has antiviral activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.15%
- CAS No.: 352554-02-0
- Formule: C14H16N2O
- Masse moléculaire:228.29
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-15262
SRT 2104
-
HY-15452
Selisistat
-
HY-16615
SIRT-IN-1
-
HY-123033A
Nicotinamide riboside chloride
-
HY-107454
OSS_128167
-
HY-123033AR
Nicotinamide riboside chloride (Standard)
-
HY-135899
SIRT7 inhibitor 97491
-
HY-B0150
Nicotinamide
-
HY-15452A
(S)-Selisistat
-
HY-16691
AK-7
-
HY-145651
Et-29
-
HY-100591
SirReal2
Publications Citing Use of MedChemExpress (MCE) SIRT1-IN-1
More
Activité biologique
|
SIRT1 0.205 μM (IC50) |
SIRT2 11.5 μM (IC50) |
SIRT3 >100 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
>100 μM
Compound: 2
|
Inhibitory activity against human HDAC in HeLa cell extract by fluorimetric assay
Inhibitory activity against human HDAC in HeLa cell extract by fluorimetric assay
|
[PMID: 16335928] |
Chemical Information
-
CAS No. 352554-02-0
-
Appearance Solid
-
Masse moléculaire 228.29
-
Formule C14H16N2O
-
Color Light yellow to yellow
-
SMILES
O=C(C1C(NC2=C3C=C(C)C=C2)=C3CCC1)N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Chin Med
Calculus Bovis ameliorates primary sclerosing cholangitis via a dual-pronged mechanism restoring bile acid and lipid homeostasis in the gut-liver axis. [Abstract]2026 Jun 8;21(1):165. PMID: 42260527 -
J Integr Med
Berberine mitigates nonalcoholic hepatic steatosis by downregulating SIRT1-FoxO1-SREBP2 pathway for cholesterol synthesis. [Abstract]2021 Nov;19(6):545-554. PMID: 34686466
Solvant et solubilité
DMSO : 100 mg/mL (438.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (21.90 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (21.90 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3804 mL | 21.9020 mL | 43.8039 mL | 109.5098 mL |
| 5 mM | 0.8761 mL | 4.3804 mL | 8.7608 mL | 21.9020 mL | |
| 10 mM | 0.4380 mL | 2.1902 mL | 4.3804 mL | 10.9510 mL | |
| 15 mM | 0.2920 mL | 1.4601 mL | 2.9203 mL | 7.3007 mL | |
| 20 mM | 0.2190 mL | 1.0951 mL | 2.1902 mL | 5.4755 mL | |
| 25 mM | 0.1752 mL | 0.8761 mL | 1.7522 mL | 4.3804 mL | |
| 30 mM | 0.1460 mL | 0.7301 mL | 1.4601 mL | 3.6503 mL | |
| 40 mM | 0.1095 mL | 0.5475 mL | 1.0951 mL | 2.7377 mL | |
| 50 mM | 0.0876 mL | 0.4380 mL | 0.8761 mL | 2.1902 mL | |
| 60 mM | 0.0730 mL | 0.3650 mL | 0.7301 mL | 1.8252 mL | |
| 80 mM | 0.0548 mL | 0.2738 mL | 0.5475 mL | 1.3689 mL | |
| 100 mM | 0.0438 mL | 0.2190 mL | 0.4380 mL | 1.0951 mL |
SIRT1-IN-1 Related Classifications
HY-136199 Related Classifications
Powered by Bioz